Bristol-Myers Squibb 1Q Revenues: $11.3 billion (-3%)  1Q Earnings: $2.3 billion (+77%) Comments: Revenue in the quarter reflects generic erosion for Revlimid and foreign exchange impacts, partially offset by Opdivo and Eliquis sales and new product portfolio, primarily Opdualag, Abecma and Reblozyl. Revlimid sales were down 37% in the quarter to $1.75 billion. Eliquis sales were up 7% to $3.4 billion and Opdivo sales were $2.2 billion, up 15%. Orencia sales were down 4% to $764 million. Poma...